InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,762.48
(
0.42%
)
US TECH 100
19,499.20
(
0.15%
)
Dow Jones
42,330.15
(
0.04%
)
Brent Oil
71.77
(
-0.31%
)
Bitcoin
63,308.50
(
-0.03%
)
Post# of 58465
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

haiqi

Send PM Follow Ignore
Followers 0
Posts 372
Boards Moderated 0
Alias Born 03/29/2011

haiqi

Re: None

Tuesday, 05/24/2011 12:50:21 PM

Tuesday, May 24, 2011 12:50:21 PM

Post# of 58465
06/06 great day to watch

Survival in a Phase 3, randomized, double-blind study of dacarbazine with or without oblimersen (Bcl-2 antisense) in patients with advanced melanoma and low-normal serum lactate dehydrogenase (LDH) (AGENDA). Abstract #8531. Poster Session: Monday, June 6, 2011 8:00 AM-12:30 PM; Discussion Session 11:30 AM-12:30 PM.

this is the day !
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up